CYRX at a glance
Cryoport, Inc. (CYRX, SEC CIK 1124524) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as August 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cryoport, Inc. (CYRX) reported revenue of $176.2 million (down 22.9% from FY2024) and net income of $78.3 million. Diluted EPS was $1.40.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Cryoport, Inc. (CYRX) shares worth $268.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by SHELTON JERRELL on August 11, 2026 of 28,800 shares at $14.91 per share.
- In the last 90 days, CYRX insiders reported 0 open-market purchases ($0) and 1 open-market sale ($429K) on Form 4, a net sale of $429K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $176.2M
- −22.9% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$429K
- 13F holders
- 30 funds
- $268.6M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability, margin, or net income percentages provided
- Headwinds: supply chain constraints, inflation, tariffs, trade restrictions, foreign exchange, geopolitical conditions
- Outlook references cell and gene therapy expansion, strategic relationships, regulatory approvals, and CRYOPDP divestiture risks
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Carried-forward risks include business, financial-condition, and operating-performance deterioration
- CEO trading plan permits sales of up to 500,000 shares through March 12, 2027
- Director trading plan permits sales of up to 74,379 shares through July 30, 2027
AI summary of the CYRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results released August 6, 2026, covering quarter ended June 30, 2026
- Detailed financial results and management commentary provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $49.0M, up 8% YoY; H1 revenue $96.8M, up 12%, led by Life Sciences Services growth
- Services revenue rose 15% to $28.0M, with BioStorage/BioServices up 25% to $5.6M
Item 5.07: Submission of Matters to a Vote of Security Holders
- All six director nominees re-elected through the 2027 annual meeting
- Deloitte & Touche ratified as auditor for fiscal 2026, with 47,014,962 votes for
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026 announced May 4, 2026
- Financial results and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q1 revenue rose 16% to $47.8M, with Services up 18% and Products up 15%, confirming broad-based demand
- Commercial CGT revenue increased 26% to $9.1M, supported by 21 approved therapies and 766 clinical trials
AI summaries of CYRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CYRX
Don't miss the next CYRX filing
- Alerts as it files. A push when CYRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CYRX, by share count.
- Ask anything. An AI agent that reads every CYRX filing and answers with sources.
CYRX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SHELTON JERRELL | Sell | Aug 11, 2026 | 28,800 | $14.91 |
| ZECCHINI EDWARD J | M | Jun 11, 2026 | 33,600 | - |
| ZECCHINI EDWARD J | M | Jun 11, 2026 | 33,600 | $4.80 |
| ZECCHINI EDWARD J | Sell | Jun 11, 2026 | 33,600 | $14.47 |
| ZECCHINI EDWARD J | M | Jun 10, 2026 | 1,400 | - |
| ZECCHINI EDWARD J | Sell | Jun 10, 2026 | 1,400 | $15.23 |
| ZECCHINI EDWARD J | M | Jun 10, 2026 | 1,400 | $4.80 |
| Mandalam Ramkumar | Sell | Jun 8, 2026 | 23,214 | $15.44 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $228.4M | $176.2M |
| Gross Profit | - | $99.6M | $83.1M |
| Operating Income | - | -$130.9M | -$36.8M |
| Net Income | - | -$114.8M | $78.3M |
| Gross Margin | - | 43.6% | 47.1% |
| Op. Margin | - | -57.3% | -20.9% |
| Net Margin | - | -50.2% | 44.4% |
| Balance Sheet | |||
| Total Assets | $957.7M | $703.5M | $765.0M |
| Equity | $489.0M | $401.9M | $502.6M |
| ROE | - | -28.6% | 15.6% |
| Per Share | |||
| EPS | - | $-2.49 | $1.40 |
| Cash Flow | |||
| Operating CF | - | -$16.3M | -$8.6M |
| CapEx | - | $17.3M | $16.4M |
Source: XBRL data in Cryoport, Inc. (CYRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CYRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $268.6M |
| Q1 2026 | 29 | $160.9M |
| Q4 2025 | 28 | $194.4M |
| Q3 2025 | 28 | $196.7M |
| Q2 2025 | 27 | $142.4M |
| Q1 2025 | 22 | $96.1M |
| Q4 2024 | 18 | $84.0M |
| Q3 2024 | 15 | $61.0M |
- D.E. Shaw & Co+321.4K (+203%)
- BlackRock+237.5K (+6%)
- Invesco Ltd+103.9K (+107%)
- Citigroup+87.4K (+265%)
- Dimensional Fund Advisors+76.4K (+8%)
- Morgan Stanley−2.30M (-50%)
- Millennium Management−1.25M (-42%)
- Citadel Advisors LLC−27.4K (-15%)
- JPMorgan Chase & Co−9.1K (-5%)
- Raymond James Financial−4.5K (-4%)
- Two Sigma Investments+14.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CYRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | Apr 23, 2026 | - | - | - |
| 4 | Apr 8, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 25, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 16, 2026 | - | - | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Dec 12, 2025 | - | - | |
| 10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CYRX SEC filings: frequently asked questions
Are CYRX insiders buying or selling?
In the last 90 days, Cryoport, Inc. (CYRX) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $429,385 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CYRX stock?
As of June 30, 2026, the largest Cryoport, Inc. (CYRX) holders among the 13F filers tracked by SignalX were BlackRock ($66.2 million), Morgan Stanley ($35.7 million), Vanguard Capital Management LLC ($33.8 million), Millennium Management ($27.1 million), State Street Corp ($16.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CYRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cryoport, Inc. (CYRX) reported revenue of $176.2 million (down 22.9% from FY2024) and net income of $78.3 million. Diluted EPS was $1.40. The figures come from the XBRL data in the 10-K.
What did CYRX report in its latest 8-K?
Cryoport, Inc. (CYRX) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results released August 6, 2026, covering quarter ended June 30, 2026.
What are the latest CYRX SEC filings?
Cryoport, Inc. (CYRX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on August 11, 2026.
What is CYRX's SEC CIK number?
Cryoport, Inc. (CYRX)'s SEC Central Index Key (CIK) is 1124524. EDGAR lists every CYRX filing under that number.
Ask anything about CYRX
The research agent reads CYRX's filings, financials, insider trades and 13F holders, then answers with sources.